Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.

Antigens, CD / immunology CD4-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / immunology Carcinoma, Squamous Cell / immunology Disease-Free Survival Female Head and Neck Neoplasms / immunology Humans Immunologic Memory / immunology Integrin alpha Chains / immunology Lymphocytes, Tumor-Infiltrating / immunology Male Middle Aged Multivariate Analysis Neoplasm Recurrence, Local Prognosis
CD103 HNSCC Larynx Resident memory T-cell

Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 19 05 2018
accepted: 04 10 2018
pubmed: 27 10 2018
medline: 26 2 2019
entrez: 27 10 2018
Statut: ppublish

Résumé

Recurrent laryngeal squamous cell carcinomas (LSCCs) are associated with poor outcomes, without reliable biomarkers to identify patients who may benefit from adjuvant therapies. Given the emergence of tumor-infiltrating lymphocytes (TIL) as a biomarker in head and neck squamous cell carcinoma, we generated predictive models to understand the utility of CD4 Tissue microarrays were constructed from salvage laryngectomy specimens of 183 patients with recurrent/persistent LSCC and independently stained for CD4 High tumor CD103 An immune profile driven by CD103

Sections du résumé

BACKGROUND BACKGROUND
Recurrent laryngeal squamous cell carcinomas (LSCCs) are associated with poor outcomes, without reliable biomarkers to identify patients who may benefit from adjuvant therapies. Given the emergence of tumor-infiltrating lymphocytes (TIL) as a biomarker in head and neck squamous cell carcinoma, we generated predictive models to understand the utility of CD4
METHODS METHODS
Tissue microarrays were constructed from salvage laryngectomy specimens of 183 patients with recurrent/persistent LSCC and independently stained for CD4
RESULTS RESULTS
High tumor CD103
CONCLUSIONS CONCLUSIONS
An immune profile driven by CD103

Identifiants

DOI: 10.1007/s00262-018-2256-3 PMID: 30361882 PMC: PMC6375747
pubmed: 30361882
doi: 10.1007/s00262-018-2256-3
pii: 10.1007/s00262-018-2256-3
pmc: PMC6375747
mid: NIHMS996721
doi:

Substances chimiques

Antigens, CD 0
Integrin alpha Chains 0
alpha E integrins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213-220

Subventions

Organisme : NIH HHS
ID : F31-DE-027600-01
Pays : United States
Organisme : NIDCR NIH HHS
ID : U01 DE025184
Pays : United States
Organisme : NIDCR NIH HHS
ID : F31 DE027600
Pays : United States
Organisme : NIH HHS
ID : R01-CA194536
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA140044
Pays : United States
Organisme : NIDCD NIH HHS
ID : T32 DC005356
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NIH HHS
ID : U01-DE025184
Pays : United States
Organisme : NIH HHS
ID : P30-CA046592
Pays : United States
Organisme : NIH HHS
ID : T32-DC535615
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA194536
Pays : United States

Références

Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
N Engl J Med. 1991 Jun 13;324(24):1685-90
pubmed: 2034244
Int J Cancer. 2011 Nov 15;129(10):2417-26
pubmed: 21207371
Oral Oncol. 2011 Apr;47(4):296-301
pubmed: 21356604
Laryngoscope. 2012 Jan;122(1):121-7
pubmed: 22183632
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
Oral Oncol. 2015 Jan;51(1):90-5
pubmed: 25283344
Clin Cancer Res. 2015 Feb 15;21(4):870-81
pubmed: 25492084
Cancer Immunol Res. 2015 Aug;3(8):926-35
pubmed: 25957117
J Clin Oncol. 2015 Oct 10;33(29):3262-8
pubmed: 26351339
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
Clin Cancer Res. 2016 Sep 15;22(18):4735-45
pubmed: 27091409
JAMA Oncol. 2016 Jul 21;:
pubmed: 27442865
Oral Oncol. 2016 Oct;61:159-65
pubmed: 27553942
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
J Cancer. 2017 Feb 9;8(3):332-344
pubmed: 28261333
Sci Rep. 2017 Mar 21;7:44823
pubmed: 28322245
Ann Oncol. 2017 May 1;28(5):1105-1110
pubmed: 28327951
Nat Immunol. 2017 Aug;18(8):940-950
pubmed: 28628092
Head Neck. 2017 Dec;39(12):2512-2518
pubmed: 28963806
Oral Oncol. 2018 Feb;77:83-89
pubmed: 29362129
Cancer Immunol Res. 2018 Jan 29;:null
pubmed: 29378694
Curr Oncol Rep. 2018 Mar 3;20(2):22
pubmed: 29502288
Otolaryngol Head Neck Surg. 1986 Sep;95(2):142-52
pubmed: 2954014

Auteurs

Jacqueline E Mann (JE)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.
Department of Pathology, University of Michigan, Ann Arbor, MI, USA.

Joshua D Smith (JD)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Andrew C Birkeland (AC)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Emily Bellile (E)

Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

Paul Swiecicki (P)

Department of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.

Michelle Mierzwa (M)

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

Steven B Chinn (SB)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Andrew G Shuman (AG)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Kelly M Malloy (KM)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Keith A Casper (KA)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Scott A McLean (SA)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Jeffery S Moyer (JS)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.

Gregory T Wolf (GT)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.
Rogel Cancer Center, University of Michigan, 1500 E. Medical Center Dr., 1904 Taubman Center, 48109-5312, Ann Arbor, MI, USA.

Carol R Bradford (CR)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.
Rogel Cancer Center, University of Michigan, 1500 E. Medical Center Dr., 1904 Taubman Center, 48109-5312, Ann Arbor, MI, USA.

Mark E Prince (ME)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.
Rogel Cancer Center, University of Michigan, 1500 E. Medical Center Dr., 1904 Taubman Center, 48109-5312, Ann Arbor, MI, USA.

Thomas E Carey (TE)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA.
Rogel Cancer Center, University of Michigan, 1500 E. Medical Center Dr., 1904 Taubman Center, 48109-5312, Ann Arbor, MI, USA.
Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.

Jonathan B McHugh (JB)

Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Rogel Cancer Center, University of Michigan, 1500 E. Medical Center Dr., 1904 Taubman Center, 48109-5312, Ann Arbor, MI, USA.

Matthew E Spector (ME)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA. mspector@umich.edu.
Rogel Cancer Center, University of Michigan, 1500 E. Medical Center Dr., 1904 Taubman Center, 48109-5312, Ann Arbor, MI, USA. mspector@umich.edu.

J Chad Brenner (JC)

Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, 48109-0602, MI, USA. chadbren@umich.edu.
Rogel Cancer Center, University of Michigan, 1500 E. Medical Center Dr., 1904 Taubman Center, 48109-5312, Ann Arbor, MI, USA. chadbren@umich.edu.
Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA. chadbren@umich.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes CD › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs épidermoïdes › Carcinome épidermoïde › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Mémoire immunologique › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Intégrines › Intégrines alpha › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de variance › Analyse multifactorielle › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Analysis of tumor-infiltrating CD103 resident...
questionsmedicales.fr › Diagnostic › Pronostic › Analysis of tumor-infiltrating CD103 resident...